The LH/hCG Axis in Endometrial Cancer: A New Target in the Treatment of Recurrent or Metastatic Disease

Abstract

Endometrial cancer (EC) is a hormone‐dependent cancer that currently represents the most frequent malignancy of the female reproductive tract. The involvement of steroid hormones in EC etiology and progression has been reported. More recently, gonadotropins, and, in particular LH/hCG, are emerging as novel regulators of tumor progression. In the present review, we discuss the role of the LH/hCG axis (i.e. LH/hCG and its receptors, LH/hCG‐R) in both gonadal and nongonadal tissues, in physiological and neoplastic conditions. In cancer cells, LH/hCG mainly controls cell proliferation and apoptosis. In particular, in EC LH/hCG improves cell invasiveness, through a mechanism which involves the LH/hCG‐R, which in turn activate protein kinase A and modulate integrin adhesion receptors. Indeed, the LH/hCG‐R mRNA is expressed in primary ECs and this expression correlates with LH/hCG‐induced cell invasiveness in vitro. These results lead to hypothesize that recurrent and metastatic ECs, which express LH/hCG‐R, could benefit from therapies aimed at decreasing LH levels, through Gn‐RH analogues. Hence, the LH/hCG axis could represent a prognostic factor and a new therapeutic target in EC.